Stem Cells
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rinker-Schaeffer, C. W.
Right arrow Articles by Mohler, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rinker-Schaeffer, C. W.
Right arrow Articles by Mohler, J. L.
Stem Cells, Vol. 14, No. 5, 508-516, September 1996
© 1996 AlphaMed Press


CONCISE REVIEW

The Role of Motility Proteins and Metastasis-Suppressor Genes in Prostate Cancer Progression

Carrie W. Rinker-Schaeffera, Marina A. Chekmarevaa, James L. Mohlerb

a The University of Chicago, Section of Urology, Department of Surgery, Chicago, Illinois, USA;
b Departments of Surgery (Division of Urology) and Pathology, The University of North Carolina, Chapel Hill, North Carolina, USA, and the UNC-Lineberger Comprehensive Cancer Center, The University of North Carolina, Chapel Hill, North Carolina, USA

Key Words. Prostate cancer • Metastasis • Motility • Metastasis suppression

Correspondence: Dr. Carrie W. Rinker-Schaeffer, University of Chicago, Section of Urology, MC 6038, 5841 S. Maryland Ave., Chicago, IL 60637, USA.

In 1996, an estimated 317,000 new cases of prostate cancer will be diagnosed in the United States. The incidence of prostate cancer has more than doubled in the past five years; in fact, it is estimated that aggressive screening starting at age 50 could potentially identify 10,000,000 American men with histologically localized prostate cancer. In order to reduce deaths from prostate cancer, it is necessary not only to diagnose but also to accurately predict the clinical course of an individual patient's cancer, thus allowing for more effectively directed treatment.

Acquisition of metastatic ability is a well-recognized criterion for the aggressiveness of prostate cancer. A number of molecular and cellular changes associated with the malignant progression of prostate cancer have been identified. Certain of these changes may potentially be used as markers for metastatic ability of histologically localized prostate cancer cells. This concise review will consider two parameters which are associated with the acquisition of metastatic ability: increased cellular motility and loss of metastasis-suppressor gene function. A link between these two parameters has been demonstrated and may contribute to the development of innovative approaches for predicting the metastatic ability of individual tumors.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
STEM CELLS THE ONCOLOGIST CME ALPHAMED PRESS JOURNALS
http://www.peprotech.com/
Copyright © 1996 by AlphaMed Press.